DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The "Anaphylaxis - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

Anaphylaxis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Anaphylaxis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaphylaxis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Companies Mentioned

Aquestive Therapeutics Insys Therapeutics Inc MannKind Corp Merck & Co Inc Shenox Pharmaceuticals LLC

Key Topics Covered

Introduction Report Coverage Anaphylaxis - Overview Anaphylaxis - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Anaphylaxis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Anaphylaxis - Companies Involved in Therapeutics Development Aquestive Therapeutics Insys Therapeutics Inc MannKind Corp Merck & Co Inc Shenox Pharmaceuticals LLC Anaphylaxis - Drug Profiles epinephrine - Drug Profile Product Description Mechanism Of Action R&D Progress epinephrine - Drug Profile Product Description Mechanism Of Action R&D Progress epinephrine - Drug Profile Product Description Mechanism Of Action R&D Progress epinephrine - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Antagonize FcgR1 for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Antagonize FcgRIIa for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile Product Description Mechanism Of Action R&D Progress SHX-008 - Drug Profile Product Description Mechanism Of Action R&D Progress XL-499 - Drug Profile Product Description Mechanism Of Action R&D Progress Anaphylaxis - Dormant Projects Anaphylaxis - Product Development Milestones Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/t24hc4/anaphylaxis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006395/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Allergy Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/05/2018 12:34 PM/DISC: 06/05/2018 12:34 PM

http://www.businesswire.com/news/home/20180605006395/en